节点文献

BRCA1/2基因相关乳腺癌临床用药进展

Clinical treatment progress of BRCA 1/2 mutation-associated breast cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 丁淑云袁斌王欣胡珀

【Author】 DING Shu-yun;YUAN Bin;WANG Xin;HU Po;Department of Pharmacy,Huaian Huaiyin Hospital;China Pharmaceutical University;Huaian Institute for Drug and Food Control;

【机构】 淮安市淮阴医院药剂科中国药科大学淮安市食品药品检验所

【摘要】 乳腺癌易感基因BRCA是与乳腺癌相关的重要抑癌基因,其生物功能广泛,对细胞周期、基因转录、DNA修复等功能均有影响。BRCA基因相关乳腺癌由于其恶性程度较高且多为遗传性疾病而引起人们重视。目前针对该类疾病的临床治疗药物种类较多,包括传统的癌症治疗药物烷化剂、铂类药物、紫杉醇类药物等。近年来药物联用及分子靶向治疗的发展也为此类癌症患者带来希望。

【Abstract】 The breast cancer susceptibility gene(BRCA) is an important anti-oncogene related to breast cancer.The biological function of BRCA are extensive,which can influence the cell cycle,gene transcription and expression,DNA damage and reparation.BRCA mutation-associated breast cancer with highly malignant degree and hereditary which has attracted much attention.Currently there are many sorts of drugs were used to treat these diseases,including traditional cancer drugs-alkylating agents,platinum-based drugs,taxol drugs,etc.In recent years,drug combination and the development of molecular targeted therapy also have brought hope for these patients.

  • 【文献出处】 中国新药与临床杂志 ,Chinese Journal of New Drugs and Clinical Remedies , 编辑部邮箱 ,2015年03期
  • 【分类号】R737.9
  • 【被引频次】11
  • 【下载频次】481
节点文献中: 

本文链接的文献网络图示:

本文的引文网络